Company News

AusBiotech says life sciences is the ‘sleeping giant’ of Australian economy March 27, 2025

AusBiotech says that while the 2025-26 Budget did not include significant new commitments for Australia’s life sciences sector, it remains steadfast in its advocacy to unlock this critical sector's full potential.

Mesoblast says its FDA-approved mesenchymal stromal cell therapy available for sale in the US March 27, 2025

Mesoblast (ASX:MSB) has announced that its FDA-approved Ryoncil (remestemcel-L) mesenchymal stromal cell therapy is now available for purchase in the US.

Neuren initiates development of NNZ-2591 to treat HIE in newborns March 27, 2025

Neuren Pharmaceuticals (ASX:NEU) has initiated the development of NNZ-2591 to treat hypoxic-ischemic encephalopathy.

Amplia Therapeutics reports updated data from pancreatic cancer trial March 27, 2025

Amplia Therapeutics (ASX:ATX) has reported updated data from its ongoing Phase 2a ACCENT clinical trial investigating its FAK inhibitor narmafotinib in combination with standard-of-care chemotherapy in treating advanced pancreatic cancer.

Clinuvel announces positive preliminary results for PRÉNUMBRA Instant in stroke patients March 27, 2025

Clinuvel (ASX:CUV) has released preliminary results from its second clinical study investigating its drug afamelanotide as a treatment for arterial ischaemic stroke.

First patient dosed in Immutep’s TACTI-004 Phase 3 non-small cell lung cancer trial March 25, 2025

Immutep (ASX:IMM) has announced that the first patient has been successfully dosed in its pivotal TACTI-004 Phase 3 trial.

Chimeric announces US patent allowed for CHM CDH17 technology March 25, 2025

Australian cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that the US Patent and Trademark Office has allowed the issuance of a patent application covering the company's CHM CDH17 chimeric antigen receptor technology.

Nanotechnology could improve odds in treating aggressive breast cancers March 25, 2025

University of Queensland researchers are designing nanotechnology they believe could improve how we treat the most aggressive form of breast cancer.

Noxopharm expands collaboration with Hudson Institute March 25, 2025

Noxopharm (ASX:NOX) has announced an expanded work program for 2025 with its strategic partner, Melbourne’s Hudson Institute of Medical Research.

Opthea now managing the fallout of clinical trial result March 25, 2025

Opthea (ASX:OPT) has reported negative outcomes from its pivotal Phase 3 clinical trial involving the combination of its sozinibercept with Bayer's EYLEA (aflibercept) for treating wet age-related macular degeneration.

Immutep confirms presentation of pivotal TACTI-004 trial at major international meeting March 20, 2025

Late-stage immunotherapy company Immutep (ASX:IMM) has announced an upcoming poster presentation for the pivotal TACTI-004 Phase 3 trial.

Osteopore enhances strategic refocus with early cessation of dental grant project March 20, 2025

Australian-Singaporean regenerative medicine company Osteopore (ASX:OSX) has confirmed the early cessation of its $18.7 million clinical-industrial partnership project following a strategic review.

Most Read

New Stories

AusBiotech says life sciences is the ‘sleeping giant’ of Australian economy

Mesoblast says its FDA-approved mesenchymal stromal cell therapy available for sale in the US

Neuren initiates development of NNZ-2591 to treat HIE in newborns

Amplia Therapeutics reports updated data from pancreatic cancer trial

Clinuvel announces positive preliminary results for PRÉNUMBRA Instant in stroke patients

First patient dosed in Immutep’s TACTI-004 Phase 3 non-small cell lung cancer trial

Chimeric announces US patent allowed for CHM CDH17 technology

Sign In